Compare GNTX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNTX | MIRM |
|---|---|---|
| Founded | 1974 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | GNTX | MIRM |
|---|---|---|
| Price | $23.93 | $91.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $29.00 | ★ $97.55 |
| AVG Volume (30 Days) | ★ 2.2M | 833.6K |
| Earning Date | 01-30-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $2,431,504,922.00 | $471,794,000.00 |
| Revenue This Year | $11.92 | $54.25 |
| Revenue Next Year | $4.87 | $21.09 |
| P/E Ratio | $14.09 | ★ N/A |
| Revenue Growth | 3.00 | ★ 53.66 |
| 52 Week Low | $20.28 | $36.88 |
| 52 Week High | $29.38 | $93.70 |
| Indicator | GNTX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 72.63 |
| Support Level | $23.35 | $85.98 |
| Resistance Level | $24.92 | $91.80 |
| Average True Range (ATR) | 0.56 | 3.82 |
| MACD | -0.02 | 1.15 |
| Stochastic Oscillator | 45.19 | 88.20 |
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.